Valuation: Novo Nordisk A/S

Market Cap 1,426B 218B 191B 176B 163B 308B 20,805B 314B 2,103B 826B 10,249B 819B 801B 35,235B P/E 2026 *
14.2x
P/E 2027 * 15.2x
Enterprise Value 1,553B 238B 208B 192B 177B 336B 22,659B 342B 2,290B 899B 11,163B 892B 873B 38,375B EV / Sales 2026 *
5.3x
EV / Sales 2027 * 5.19x
Free-Float
71.32%
Yield 2026 *
3.52%
Yield 2027 * 3.42%

Last Transcript: Novo Nordisk A/S

1 day+0.66%
1 week-1.42%
Current month+2.43%
1 month+13.83%
3 months+33.91%
6 months-15.52%
Current year-0.92%
1 week 317.05
Extreme 317.05
330.5
1 month 277.2
Extreme 277.2
332.65
Current year 224.25
Extreme 224.25
409.95
1 year 224.25
Extreme 224.25
464.6
3 years 224.25
Extreme 224.25
1,033.2
5 years 224.25
Extreme 224.25
1,033.2
10 years 109.1
Extreme 109.1
1,033.2
Manager TitleAgeSince
Chief Executive Officer 56 2025-08-06
Director of Finance/CFO 55 2018-02-14
Chief Tech/Sci/R&D Officer - 2025-11-04
Director TitleAgeSince
Director/Board Member 61 2017-03-22
Director/Board Member 51 2018-03-21
Director/Board Member 61 2022-03-23
Date Insider Type Main position Quantity % Market Cap.
Nov. 17Others 18,634 0.0005%
Nov. 17Sell 8,160 0.0002%
Nov. 17Buy

Director

6,450 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+0.66%-1.42%-29.26%-39.30% 218B
-2.33%-2.09%+50.33%+162.29% 1,060B
-0.82%-2.30%+62.97%+61.11% 619B
-0.73%-4.98%+27.22%+84.46% 438B
+0.33%-1.17%+27.98%+26.90% 333B
-0.02%-2.85%+25.27%+44.88% 282B
-3.89%-11.22%+20.78%+26.07% 267B
-0.06%-2.88%+20.98%+61.70% 196B
-3.72%-1.10%+13.35%+71.53% 161B
-0.33%-0.62%-6.25%-32.26% 138B
Average -0.79%-2.98%+21.34%+46.74% 371.17B
Weighted average by Cap. -0.54%-2.87%+33.74%+77.06%

Financials

2026 *2027 *
Net sales 293B 44.86B 39.24B 36.19B 33.43B 63.43B 4,279B 64.5B 432B 170B 2,108B 168B 165B 7,246B 299B 45.76B 40.03B 36.92B 34.1B 64.71B 4,365B 65.79B 441B 173B 2,150B 172B 168B 7,392B
Net income 99.11B 15.16B 13.26B 12.23B 11.3B 21.43B 1,446B 21.79B 146B 57.38B 712B 56.92B 55.68B 2,448B 94.05B 14.39B 12.58B 11.61B 10.72B 20.34B 1,372B 20.68B 139B 54.46B 676B 54.01B 52.84B 2,324B
Net Debt 127B 19.44B 17.01B 15.69B 14.49B 27.49B 1,854B 27.95B 187B 73.6B 913B 73B 71.41B 3,140B 126B 19.29B 16.87B 15.57B 14.38B 27.28B 1,840B 27.74B 186B 73.03B 906B 72.44B 70.86B 3,116B
Logo Novo Nordisk A/S
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).
Employees
67,900
Date Price Change Volume
26-07-10 DKK 322.25 +0.66% 2,598,903
26-07-09 DKK 320.15 -0.93% 2,907,910
26-07-08 DKK 323.15 -1.31% 4,285,696
26-07-07 DKK 327.45 +1.98% 3,717,003
26-07-06 DKK 321.10 -1.77% 3,239,904
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
322.25DKK
Average target price
316.91DKK
Spread / Average Target
-1.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NOVO B Stock